Earnings summaries and quarterly performance for Prime Medicine.
Executive leadership at Prime Medicine.
Board of directors at Prime Medicine.
Research analysts covering Prime Medicine.
Recent press releases and 8-K filings for PRME.
Prime Medicine Reprioritizes Pipeline and Outlines Clinical Development Timelines
PRME
CEO Change
New Projects/Investments
Guidance Update
- Prime Medicine's CEO, who joined in January 2024 and became CEO in May 2025, has reprioritized the company's pipeline to focus on liver programs for Wilson disease and alpha-1 antitrypsin deficiency, as well as an ex vivo CAR T program with BMS.
- The company emphasizes its prime editing technology as the most versatile and safest way to edit the genome, capable of correcting various mutations that CRISPR and base editing cannot, with no evidence of off-target editing in extensive analyses for its first IND program.
- Clinical timelines include an Investigational New Drug (IND) application for Wilson disease in the first half of 2026 and for alpha-1 antitrypsin deficiency by mid-2026, with data for both programs expected in 2027.
Dec 2, 2025, 4:15 PM
Prime Medicine CEO Discusses Strategic Focus and Pipeline Advancement
PRME
New Projects/Investments
Management Change
Guidance Update
- Allan Reine became CEO of Prime Medicine in May 2025 and has since streamlined the company's pipeline to focus on programs with high technical and commercial success probability.
- The company's core focus is now on Wilson disease, alpha-1 antitrypsin deficiency, cystic fibrosis, and an ex vivo CAR T program with BMS. Deprioritized programs, including those in ocular, hearing loss, and neurological diseases, may be considered for future partnerships.
- Prime Medicine anticipates filing an IND for Wilson disease in the first half of 2026 and an IND or CTA for alpha-1 antitrypsin deficiency in mid-2026. Data for both programs is expected in 2027.
- The company emphasizes its Prime Editing technology as the most versatile and safest gene editing method, capable of various corrections and large insertions, with extensive off-target analysis showing no evidence of off-target editing in its first IND program.
Dec 2, 2025, 4:15 PM
Prime Medicine Provides Updates on Gene Editing Programs and 2026 Catalysts
PRME
New Projects/Investments
Product Launch
Guidance Update
- Prime Medicine's CEO highlighted its Prime Editing technology as the most versatile and safest gene editing approach, capable of precise, large insertions without double-stranded breaks or bystander edits, distinguishing it from CRISPR Cas9 and Base Editing.
- The Wilson's disease program is slated for IND/CTA filing in H1 2026 with clinical data anticipated in 2027, targeting 10,000-11,000 U.S. patients with specific mutations not addressable by other gene editing technologies.
- The AATD program is expected to enter the clinic in mid-2026 with data readouts in 2027, aiming for wild-type protein correction and demonstrating high editing levels preclinically.
- For Cystic Fibrosis, preclinical data is projected for 2026, employing both AAV and LNP delivery methods to target the 10%-15% of patients whose needs are unmet by existing therapies.
- Key catalysts for the next 6-12 months include regulatory filings for Wilson's and alpha-1, patient enrollment in 2026, robust preclinical data for CF, and potential business development deals, including sizable preclinical milestones from the Bristol partnership, possibly in 2026.
Nov 18, 2025, 12:00 PM
Prime Medicine Outlines 2026 Clinical and Preclinical Milestones for Key Programs
PRME
New Projects/Investments
Guidance Update
- Prime Medicine anticipates filing IND/CTA for its Wilson's disease program in H1 2026 and initiating clinical entry for its AATD prime editor program in mid-2026, with clinical data for both programs expected in 2027.
- The company's Prime Editing technology is highlighted as the most versatile and safest gene editing method, capable of precise wild-type protein correction, differentiating it from CRISPR Cas9 and Base Editing.
- Prime Medicine is developing a universal LNP technology with a favorable preclinical profile and expects to present preclinical data for its Cystic Fibrosis program in 2026.
- The company anticipates potential sizable preclinical milestones from its partnership with Bristol in 2026, alongside a strategic focus on additional business development deals.
Nov 18, 2025, 12:00 PM
Prime Medicine Details Wilson Disease Strategy and Preclinical Data
PRME
New Projects/Investments
Product Launch
- Prime Medicine is at an inflection point with its prime editing technology, focusing initially on programs for diseases with high unmet need, including Wilson disease and alpha-one antitrypsin deficiency.
- The company plans to file an IND and/or CTA for its lead Wilson disease program (PM577) in the first half of 2026, with proof of concept efficacy data expected in 2027.
- New preclinical data for PM577, presented at AASLD 2025, demonstrated efficient correction of mutations, complete restoration of hepatic copper concentrations, and normalization of copper excretion, suggesting full restoration of ATP7B function.
- Prime Medicine estimates the global commercial opportunity for Wilson disease to be $20 billion to $40 billion+, aiming to address 60-70%+ of patients with a few prime editors.
- The modularity of Prime Medicine's platform and universal lipid nanoparticle delivery system are expected to accelerate development and reduce costs for subsequent programs, including fast followers for other Wilson disease mutations and alpha-one antitrypsin deficiency.
Nov 12, 2025, 1:00 PM
Prime Medicine Reports Q3 2025 Financial Results and Key Business Updates
PRME
Earnings
Guidance Update
Management Change
- Prime Medicine reported a net loss of $50.6 million for the third quarter of 2025, compared to a net loss of $52.5 million for the same period in 2024. Research and Development (R&D) expenses increased to $44.0 million in Q3 2025 from $40.3 million in Q3 2024, while General and Administrative (G&A) expenses decreased to $11.2 million from $14.1 million.
- As of September 30, 2025, the company's cash, cash equivalents, and investments totaled $213.3 million, which is expected to fund operating expenses and capital expenditure requirements into 2027.
- In August 2025, Prime Medicine nominated PM647 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), with an investigational new drug application (IND) and/or clinical trial application (CTA) filing anticipated in mid-2026 and initial clinical data expected in 2027.
- New preclinical data for PM577 in Wilson's Disease (WD) will be presented, with an IND/CTA filing projected for H1 2026 and initial clinical data also expected in 2027.
- Matthew Hawryluk, Ph.D., M.B.A. was appointed as Chief Business Officer in November 2025, responsible for business development, corporate strategy, and alliance management.
Nov 7, 2025, 12:27 PM
Chardan's 9th Annual Genetic Medicines Conference Discusses Genome Editing Advancements and Commercial Strategies
PRME
New Projects/Investments
Product Launch
- The conference highlighted the maturation of genome editing technologies, with participants emphasizing the coexistence of various approaches and the importance of product differentiation.
- Delivery technologies were identified as critical, with LNPs emerging as a leading platform for in vivo delivery due to their platform advantages and potential for lower cost of goods, though their profiles vary significantly.
- Discussions focused on the commercial viability of "one and done" gene editing therapies, stressing the need for early consideration of pricing strategies, cost of goods (COGS), and the evolving payer landscape to ensure success.
- Companies are expanding their focus beyond liver-directed programs to targets like the CNS, leveraging platform capabilities to accelerate development and broaden applications.
Oct 21, 2025, 12:45 PM
Prime Medicine Discusses Pipeline Prioritization, Technology, and Financial Outlook
PRME
New Projects/Investments
Guidance Update
- Prime Medicine is advancing its Prime Editing platform, a next-generation gene editing approach that offers versatility in writing new genetic code and enhanced safety due to single-stranded breaks and lack of off-target editing.
- The company has prioritized its pipeline, focusing on liver programs for Wilson's disease (PM577) and alpha-1 antitrypsin deficiency, with IND filings guided for H1 2026 and mid-2026, respectively, and clinical data for both expected in 2027.
- Despite "exceptional data" in two patients, Prime Medicine discontinued its Chronic Granulomatous Disease (CGD) program due to its ultra-orphan status and insufficient commercial viability, a decision that helps de-risk the broader platform.
- Prime Medicine reported a cash runway of approximately $260 million at the end of Q2, which is projected to fund operations into 2027.
Oct 14, 2025, 11:00 AM
Prime Medicine Discusses Pipeline Reprioritization and Clinical Timelines
PRME
New Projects/Investments
Guidance Update
- Prime Medicine is focused on advancing its prime editing technology, a versatile and safe gene editing approach that makes single-stranded DNA breaks, avoiding off-target editing and chromosomal rearrangements.
- The company has reprioritized its pipeline to liver programs, with Wilson's disease (PM577) and alpha-1 antitrypsin deficiency expected to enter the clinic in the first half and mid-2026, respectively, with Wilson's data anticipated in 2027.
- Despite strong initial clinical data, Prime Medicine discontinued its chronic granulomatous disease (CGD) program due to its ultra-orphan nature and limited commercial opportunity.
- Prime Medicine reported a cash runway of approximately $260 million at the end of Q2 2025, which is projected to extend into 2027.
Oct 14, 2025, 11:00 AM
Prime Medicine Provides Update on Prime Editing Platform, Pipeline, and Financial Outlook
PRME
Guidance Update
New Projects/Investments
- Prime Medicine is advancing its Prime Editing platform, described as a next-generation gene editing approach that makes single-stranded breaks, can write new genetic code, and offers high versatility and safety without off-target editing or chromosomal rearrangements.
- The company's lead in vivo programs, PM577 for Wilson's disease and a program for alpha-1 antitrypsin deficiency, are targeted for IND filings in H1 2026 and mid-2026, respectively, with clinical data for both anticipated in 2027.
- Prime Medicine discontinued its chronic granulomatous disease (CGD) program despite achieving "exceptional data" in two patients, due to the ultra-orphan nature of the disease and limited commercial opportunity.
- The clinical data from the CGD program demonstrated high-efficiency editing in an ex vivo setting, de-risking the Prime Editing platform's effectiveness and shifting the focus to delivery, particularly in the liver using lipid nanoparticles (LNPs).
- The company reported a cash runway into 2027 with approximately $260 million at the end of Q2.
Oct 14, 2025, 11:00 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more